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Abstract
Background: The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is a core questionnaire
designed to evaluate health-related quality of life (HRQoL) of cancer patients participating in international clinical trials. It is
available in several languages including Danish. The EORTC QLQ-TC26 is a supplemental module developed for patients
with testicular cancer, which can be useful in clinical trials. Despite Denmark holding a high prevalence and incidence of
testicular cancer, no Danish translation was previously available. This paper describes the translation process and pilot
testing of the Danish translation of QLQ-TC26.
Methods: The English language EORTC QLQ-TC26 was translated into Danish using forward and backward procedures
with reconciliation. The translated instrument was assessed in semi structured cognitive interviews in a sample of 10
patients ages 20–56 receiving treatment for testicular cancer.
Results: In one round of pilot testing, no changes were required for the Danish translation based upon patient comments.
The Danish translation was agreed by participants to be both culturally acceptable and semantically comprehensible.
Conclusions: The pilot testing of the Danish translation of the EORTC QLQ-TC26 was performed in one round of
patient interviews; these results support the Danish translation as a comparable instrument to the English language
version. However, further validation is required to ensure complete equivalency. These results support the use of the
EORTC QLQ-TC26 in future clinical trials conducted with Danish-speaking patients.
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Background
Testicular cancer (TC) is the most common cancer in
men between the ages of 15–45 years [1]. During and after
treatment, some TC patients and survivors may face detri-
mental complications, including anxiety, depression, fa-
tigue, infertility and sexual dysfunction [2, 3], while others
report health-related quality of life (HRQoL) values similar
to the general population when using EORTC HRQoL
measuring instruments [3, 4]. However, these prior find-
ings have not evaluated the specific features unique to TC,
and many individuals experience lowered HRQoL as re-
sult of illness or treatment [5].
The European Organization for Research and Treat-
ment of Cancer QLQ-C30 (EORTC) is a widely-utilized
core questionnaire designed to evaluate HRQoL in can-
cer patients participating in international clinical trials
[6–8]. It is the inherent design of the QLQ-C30 to serve
as an all-encompassing keystone for the measurement of
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HRQoL; this instrument may be supplemented with vali-
dated distinct subscales for specific diagnoses and pa-
tient populations for more nuanced results [9]. The
EORTC QLQ-TC26 is a supplementary module for the
EORTC QLQ-C30 for the assessment of HRQoL in TC
patients and TC-specific symptoms currently in Phase IV
international field testing [10]. This instrument consists of
26 questions addressing quality of life within the following
subscales: treatment side effects, treatment satisfaction,
future perspective, job problems, family problems, in-
fertility, communication, body image problems, sexual
activity, sexual problems, sexual enjoyment, and tes-
ticular implant satisfaction. Answers are selected
based upon patient-reported severity or intensity of
TC-specific symptoms on a four-point Likert scale
from ‘not at all’ to ‘very much’, with a reference frame
of 1 week [11]. This instrument is designed for the
use of testicular cancer patients both receiving active
treatment, and survivors of testicular cancer, making
it a versatile tool for this population. The instrument
was additionally designed to be used in coordination
with the original EORTC QLQ-C30 30-item instru-
ment for thorough HRQoL assessment; as such, the
26 items are numbered for usage after the EORTC
QLQ-C30, as questions 31–56.
Currently, the EORTC QLQ-TC26 is available in sev-
eral languages, including Dutch, English, German, Italian
and Spanish [10]. However, this specific instrument is
not available in a Danish translation. Denmark holds the
second highest incidence and prevalence of testicular
cancer in Europe [12, 13], and this population is easily
followed due to the presence of a national testicular can-
cer registry [14]. As such, the testicular cancer popula-
tion in Denmark is a valuable population for further
studies on QoL. A Danish translation of the QLQ-TC26
would allow for comprehensive evaluation of HRQoL in
TC patient populations, as well as encourage compari-
son and coordination between different HRQoL data
resources.
The aim of this study was to develop and pilot test a
Danish translation of the English language version of the
EORTC QLQ-TC26 for inclusion in future clinical trials.
Methods
Translation
Research collaboration represented by the authors of this
article was established between a Danish steering group
and representatives from the EORTC Quality of Life
Group to ensure appropriate methodology and transla-
tion protocol.
The English-language EORTC QLQ-TC26 was trans-
lated according to the protocol and guidelines outlined
by the EORTC Quality of Life Group [15]. The transla-
tion was produced by a forward–backward procedure, in
which two native Danish speakers with academic English
translation experience independently translated the Eng-
lish EORTC QLQ-TC26 into Danish [15–17]. The two
translations were compared by the steering group for
any discrepancies. Consensus was achieved based on the
following criteria: the translation should be in accordance
with the original English text; Danish culture must be
taken into account in choosing the right words and in
construction of sentences; traditional standards are to be
considered in terms of prior communication with patients
and health care classification in response categories.
The compiled result was then back-translated by two
native English speakers fluent in Danish with experience
in academic Danish translation back into English. All
translations, and a report detailing action thus far, were
then sent to a representative from the EORTC Quality
of Life Group, and were proofread by an independent
translator. Results were described in an interim report,
and then were assessed via pilot testing.
Pilot testing
Pilot testing of the Danish translated version of EORTC
QLQ-TC26 was performed by individual semi-structured
interviews with 10 patients. This sample size was de-
cided based on the recommended number of partici-
pants for translation pilot testing specified in the
EORTC translation protocol [15]. The interviews were
performed by a research nurse specialized in oncology.
The interviews took place on the clinical ward after the
patient’s consultation with an oncologist consecutively in
the order they were scheduled in clinic for the relevant
day. Inclusion criteria for patients were as follows: 1) A
diagnosis of TC, 2) Ability to speak and read the Danish
language, 3) At least one prior treatment with chemo-
therapy. Due to ethical concerns, patients who were
about to receive a negative message (e.g. progression of
disease) were not addressed for interview.
The patients were introduced to the project by the
interviewer, and the aim of the project was described be-
fore the patient agreed to participate. Ten patients were
invited to participate, of which all consented and agreed
to participate. This research was exempt from review by
an institutional review board or ethical authority under
Danish law. Informed consent was obtained from all in-
dividual participants.
In the interview, the patients first filled in the ques-
tionnaire on their own and were asked to mark ques-
tions they found difficult or problematic. According to
the topic guide for the interviews, the interviewer dis-
cussed each marked item on the questionnaire asking
participants whether the translated item was: 1) difficult
to answer; 2) confusing; 3) difficult to understand; or 4)
upsetting/offensive. Participants were additionally asked
how they would phrase the question in their own words.
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If a participant had any comments on the translated
item, they were asked to rephrase the question in a way
that would be less confusing, more easily understood,
and/or less upsetting or offensive. The interviewer add-
itionally asked the patients about their general thoughts
related to answering the questions and what problems
they had experienced in order to identify the reasoning
behind their comments. The interviewer kept notes
throughout the interview, summarized and repeated
their notes for the patient before closing the interview.
Data analysis
The steering group reviewed the results of all interviews,
and made decisions based on all questions identified as
problematic by participants.
Data analysis was performed according to the proce-
dures used in the translation manual from the EORTC
Quality of Life Group [15]. The steering committee
compiled a summary of participant comments from pilot
testing interviews. All items that elicited comments from
participants were examined to determine the nature of
the problem, and what suggestions were made for alter-
nate phrasing. This report was then sent to the EORTC
Quality of Life Group, and results were discussed both
within the steering committee, and then with the
EORTC Quality of Life Group. If changes were deter-
mined necessary, further re-testing would be performed.
Compliance with ethical standards
Disclosure of interest
The authors declare that they have no conflicts of interest.
Ethical approval
All procedures performed in studies involving human
participants were in accordance with the ethical stan-
dards of the institutional and/or national research com-
mittee and with the 1964 Helsinki declaration and its
later amendments or comparable ethical standards. This
research was exempt from review by an institutional re-
view board or ethical authority under Danish law.
Table 1 Characteristics of patients
Age Education Civil status
56 Skilled worker Married/couple
38 Higher education (3–4 years) Single
42 Higher education (3–4 years) Married/couple
20 Student Single
52 Higher education (> = 5 years) Married/couple
52 Skilled worker Single
24 Higher education (3–4 years) Single (girlfriend)
46 Higher education (3–4 years) Married/couple
48 Higher education (3–4 years) Married/couple
35 Primary school Single
Table 2 Comments obtained for each question and patient
Question nr. Difficulty understanding Confusing Suggested wording
31 A little confusing as you can lose hair as a man
regardless connection to cancer
Have you lost hair in
relation to your treatment?
32 Is it only interesting if it is experienced as a problem?
What if you experience a change but not think
of it as a problem
38 A little confusing only to ask about hearing badly,
what about tinnitus – it is important – but will it
be covered by this question?
39 Wording of the time dimension.
Shall it be understood for the past
or the present time?
40 (As in question 39)
42 (As in question 39)
45 Difficult to understand
what the question is about
The word ‘disruption’ seems wrong.
Think ‘affect’ would be more appropriate
Were you worried about how
it will affect your family life?
49 Confusing wording regarding the ‘time’ To what degree have you
been interested in …?
50 Confusing wording regarding the ‘time’ To what degree have you
been interested in …?
Other Comments Is it relevant to relate answers to the time dimension”
in the past week” and the grammatically framing of the
time dimension in the questions?
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Informed consent
Informed consent was obtained from all individual par-
ticipants included in the study.
Results
The forward translation was performed by two native
Danes with academic experience in translation of Eng-
lish texts with the Danish Cancer Society. In eight items
full agreement was found in translation between both
translators. In 16 items, minor differences were found in
word choice, but there was no difference found in mean-
ing. In 2 items, different words were utilized to describe
symptom with slight alteration in interpretation, which
were discussed to determine the most accurate state-
ment in reconciliation with the English text. The follow-
ing decisions were made: in item 39, ‘…the medical
treatment…?’ was chosen to be utilized over ‘…the doc-
tor’s treatment…?’, and in the introductory text ‘Patients
sometimes report…’ was chosen to be utilized over ‘Pa-
tients sometimes tell…’.
The backwards translation was performed by two bi-
lingual native English speakers, one originating from the
USA and the other from the UK. Both have experience
in translation of Danish texts with the Danish Cancer
Society. In 10 items there was full agreement in transla-
tion between the two translations and in accordance
with the original English text. In 15 items there were
minor differences in word choice with no difference in
meaning in comparison to the original English text. In
one item, the backward translation resulted in a different
meaning in comparison to the original English text. The
backward translation item 24, ‘to what extent was sex
enjoyable for you,’ resulted in ‘..was sex pleasant ..’ and ‘..
was sex comfortable ..’. This was considered not to re-
flect the original meaning. The exact Danish word for
‘enjoyable’ was chosen from one of the forward transla-
tions and changed in the question item. This was the
only change made to the original Danish text, and no
further changes were determined to be required from
the translators.
Pilot test interviews lasted between 15 and 20 min
each. Patients were between the ages of 20 and 56 with
an average age of 41. Participant demographics are sum-
marized in Table 1.
Interviews elicited 11 total comments on 8 different
EORTC-TC26 questions by five distinct patients (50% of
participants). Comments could be applied to multiple
statement categories. Four comments were difficulties in
understanding, six were confusing statements, and four
were suggestions for alterations in wording. One state-
ment requested clarification in time dimensions within
the EORTC questionnaire as a whole. Table 2 summarizes
the comments for each question and patient. There were
no comments related to difficult words or upsetting
questions.
The steering group discussed the results from the 10
interviews and determined that no changes were re-
quired after discussion. Hair loss and problems with
taste or sense of smell were discussed as items that
could be either determined as unproblematic or unre-
lated to cancer treatment. Discussion between the steer-
ing group determined that changes in description would
change the inherent meaning of these statements, and
that patients will generally complete this questionnaire
Table 3 Concerns and discussion from steering group justifying changing or retaining current translation in question
Question Nr. / Topic Concern Discussion
Question 31 - Hair Loss Men may lose hair for reasons not
attributable to cancer.
Although the comment is understandable, it is of no significance for the
question. Generally, the patient shall not consider the reason for the symptom.
No change is required.
Question 32 - Problems with
Taste or Sense of Smell
Problems with taste or sense of
smell may be noted as changes
that are not necessarily problematic.
The patient’s reflection on the symptom being a problem or not
can be relevant. However, changing the word would lead to an
incorrect meaning when compared to the original English text.
No change is required.
Question 38 - Tinnitus Problems with hearing may not
adequately cover tinnitus.
We consider that ‘tinnitus’ would be captured in the question of
‘problems with hearing’ as most patients would consider it a problem.
No change is required.
Questions 39, 40, 42, 49,
50 - Time Dimension
It is unclear if the statements are
worded in past or present tense.
Two of the patients commented on the different wordings of the time
‘were you …’ or ‘have you been …’. Also, there was consideration if satisfaction
with the medical care should be related to the past or the present time.
We have decided not to make any change in the wording, as the shifts
in wording follow the original English text.
No change is required.
Question 45 - Disruption Affect may be a more appropriate
word choice than disruption.
Two patients commented on the wording of the question especially
concerning the word ‘disruption’ and one suggested to use ‘affect’ instead.
However, ‘affect’ would not be translated backwards to ‘disruption’.
We have no other Danish word that would match ‘disruption’ translated
as ‘forstyrrelse’ which was correctly translated backwards.
No change is required.
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within the context of cancer treatment and not external
causes. Tinnitus was mentioned as a symptom that may
not adequately be covered, however, the steering group
believed it was well-covered under the questionnaire
item ‘problems with hearing’. Lastly, the word ‘disrup-
tion’ was discussed as a potentially inappropriate word
choice, however, no other Danish word was available
that could correctly be translated backwards. All justifi-
cations are summarized in Table 3. The final Danish
translation has since been submitted to the EORTC
Quality of Life Group.
Discussion
In this paper, we have outlined the process of trans-
lating and pilot testing a Danish language translation
of the EORTC QLQ-TC26 QoL instrument utilizing
the EORTC Quality of Life Group translation proced-
ure [15]. The end result translation was consistent
with the EORTC-TC26 English language version. This
pilot testing of the Danish translation of EORTC
QLQ-CT26 was performed in one round of patient
interviews with no changes required in the question-
naire’s wording. The EORTC QLQ-TC26 Danish
translation is now available for use in cancer clinical
trials through collaborative agreements with the
EORTC Quality of Life Group.
Strengths of this translation and pilot test include
utilization of the official translation procedure for an
EORTC instrument [10, 15]. While a small population
(n = 10) was identified from a single site, the criteria
have been met for an official standardized EORTC trans-
lation pilot test [15]. This pilot testing protocol is limited
as interviews were not recorded and transcribed verba-
tim. However, the interviewer completed thorough
notes, and repeated the contents of these notes to partic-
ipants, ensuring accuracy of interview content and
meaning throughout the pilot testing process.
There has been prior commentary about the limitations
of the EORTC QLQ-TC26 as a new instrument [4], how-
ever, with more time and sufficient use, the EORTC
QLQ-TC26 will be better able to be assessed for utility in
testicular-cancer specific QoL measurement. Phase IV field
testing for the EORTC QLQ-TC26 is currently underway
to assess for dimensionality, reliability, sensitivity to change
and instrument validity [10].
Conclusions
In conclusion, the pilot testing of the Danish translation
of the EORTC QLQ-TC26 was performed in one round of
patient interviews; these results support the Danish trans-
lation as a comparable instrument to the English language
version. The EORTC QLQ-TC26 has begun to see use in
clinical trials [EudraCT2014–003930-17][NCT02304575],
and the results of this translation and pilot testing process
provide preliminary support for the use of the EORTC
QLQ-TC26 Danish translation in testicular cancer clinical
trials. Next steps will include the utilization of this QoL
tool in clinical trials with testicular cancer patients amongst
a Danish-speaking population, as well as validation of this
translation in a larger population of Danish-speaking
patients.
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